Cytochrome P450-activated prodrugs

NADPH–cytochrome P450 oxidoreductase: Prototypic member of the diflavin reductase family

(2012) Takashi Iyanagi et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Bioactivation of Fluorinated 2-Aryl-benzothiazole Antitumor Molecules by Human Cytochrome P450s 1A1 and 2W1 and Deactivation by Cytochrome P450 2S1

(2012) Kai Wang et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Metabolic Activation of Prasugrel: Nature of the Two Competitive Pathways Resulting in the Opening of Its Thiophene Ring

(2012) Patrick M. Dansette et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Overcoming Clopidogrel Resistance: Discovery of Vicagrel as a Highly Potent and Orally Bioavailable Antiplatelet Agent

(2012) Jiaqi Shan et al.   JOURNAL OF MEDICINAL CHEMISTRY

More Codeine Fatalities After Tonsillectomy in North American Children

(2012) L. E. Kelly et al.   PEDIATRICS

Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity

(2011) Klaus Pors et al.   CHEMICAL COMMUNICATIONS

Cytochromes P450 Catalyze Both Steps of the Major Pathway of Clopidogrel Bioactivation, whereas Paraoxonase Catalyzes the Formation of a Minor Thiol Metabolite Isomer

(2011) Patrick M. Dansette et al.   CHEMICAL RESEARCH IN TOXICOLOGY

CYP2C9-Mediated Metabolic Activation of Losartan Detected by a Highly Sensitive Cell-Based Screening Assay

(2011) A. Iwamura et al.   DRUG METABOLISM AND DISPOSITION

CYP2S1 and CYP2W1 Mediate 2-(3,4-Dimethoxyphenyl)-5-Fluorobenzothiazole (GW-610, NSC 721648) Sensitivity in Breast and Colorectal Cancer Cells

(2011) B. S. Tan et al.   MOLECULAR CANCER THERAPEUTICS

Reply to: "Paraoxonase-1 and clopidogrel efficacy"

(2011) Heleen J Bouman et al.   NATURE MEDICINE

Paraoxonase-1 and clopidogrel efficacy

(2011) Patrick M Dansette et al.   NATURE MEDICINE

The Bioreductive Prodrug PR-104A Is Activated under Aerobic Conditions by Human Aldo-Keto Reductase 1C3

(2010) C. P. Guise et al.   CANCER RESEARCH

Formation and Fate of a Sulfenic Acid Intermediate in the Metabolic Activation of the Antithrombotic Prodrug Prasugrel†

(2010) Patrick M. Dansette et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Biotransformation of Prasugrel, a Novel Thienopyridine Antiplatelet Agent, to the Pharmacologically Active Metabolite

(2010) K. Hagihara et al.   DRUG METABOLISM AND DISPOSITION

Efficient Hypoxic Activation of the Anticancer Agent AQ4N by CYP2S1 and CYP2W1

(2010) C. R. Nishida et al.   MOLECULAR PHARMACOLOGY

Paraoxonase-1 is a major determinant of clopidogrel efficacy

(2010) Heleen J Bouman et al.   NATURE MEDICINE

DNA Cross-Links in Human Tumor Cells Exposed to the Prodrug PR-104A: Relationships to Hypoxia, Bioreductive Metabolism, and Cytotoxicity

(2009) R. S. Singleton et al.   CANCER RESEARCH

Metabolic Oxidative Cleavage of Thioesters: Evidence for the Formation of Sulfenic Acid Intermediates in the Bioactivation of the Antithrombotic Prodrugs Ticlopidine and Clopidogrel

(2009) Patrick M. Dansette et al.   CHEMICAL RESEARCH IN TOXICOLOGY

A Predominate Role of CYP1A2 for the Metabolism of Nabumetone to the Active Metabolite, 6-Methoxy-2-naphthylacetic Acid, in Human Liver Microsomes

(2009) M. Turpeinen et al.   DRUG METABOLISM AND DISPOSITION

Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite

(2009) M. Kazui et al.   DRUG METABOLISM AND DISPOSITION

Potent and Highly Selective Hypoxia-Activated Achiral Phosphoramidate Mustards as Anticancer Drugs

(2008) Jian-Xin Duan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pradefovir: A Prodrug That Targets Adefovir to the Liver for the Treatment of Hepatitis B

(2008) K. Raja Reddy et al.   JOURNAL OF MEDICINAL CHEMISTRY

Improvement of Cyclophosphamide Activation by CYP2B6 Mutants: From in Silico to ex Vivo

(2008) T.-A. Nguyen et al.   MOLECULAR PHARMACOLOGY

Prodrugs: design and clinical applications

(2008) Jarkko Rautio et al.   NATURE REVIEWS DRUG DISCOVERY